AGF Management Ltd. Purchases 942 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AGF Management Ltd. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 281.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,277 shares of the biopharmaceutical company's stock after purchasing an additional 942 shares during the quarter. AGF Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $910,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of REGN. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $28,000. Private Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 39 shares during the period. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $49,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.1 %

NASDAQ:REGN traded up $7.40 during mid-day trading on Wednesday, hitting $672.36. 674,993 shares of the company's stock were exchanged, compared to its average volume of 626,763. The company has a 50 day simple moving average of $692.84 and a 200-day simple moving average of $823.99. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $73.51 billion, a P/E ratio of 17.56, a PEG ratio of 2.34 and a beta of 0.27.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the company earned $11.86 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analysts Set New Price Targets

A number of research firms recently commented on REGN. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Bank of America reaffirmed an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.